KYIV. Aug 31 (Interfax-Ukraine) – Public joint-stock company Farmak pharmaceutical company (Kyiv) does not plan to launch vaccine production in the near term, Farmak CEO Augustin Dubnicka has said.
“Farmak does not plan to develop these projects in the near future,” he said in an interview with Interfax-Ukraine.
“From our side, as a national producer, it would be more rational to create a proposal in those areas where we are competent, for example, endocrinology,” he said.
Dubnicka said that “the full-cycle production of vaccines and quality control is a scientifically and technically very sophisticated process that requires high-level specialists and large investments, which does not make it attractive to pharmaceutical companies.”
“Earlier, Farmak planned to open this production facility. It will be possible to complete the implementation of these plans in close cooperation with some foreign partners that specialize in these preparations,” he said.
Farmak is the largest pharmaceutical company in Ukraine. The ultimate beneficiary of the company is Filia Zhebrivska.
